These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27180963)

  • 1. [Significance of increased and reduced proteasome activity in the pathomechanism of selected disorders].
    Tylicka M; Matuszczak E; Karpińska M; Dębek W
    Postepy Hig Med Dosw (Online); 2016 May; 70():448-58. PubMed ID: 27180963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
    Staszczak M
    Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Proteasome Enhancement by Small Molecules.
    George DE; Tepe JJ
    Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ubiquitin-independent protein degradation in proteasomes].
    Buneeva OA; Medvedev AE
    Biomed Khim; 2018 Mar; 64(2):134-148. PubMed ID: 29723144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of proteasomes in prion disease.
    Zhu T; Hayat Khan S; Zhao D; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2014 Jul; 46(7):531-9. PubMed ID: 24829398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein degradation by the 26S proteasome system in the normal and stressed myocardium.
    Gomes AV; Zong C; Ping P
    Antioxid Redox Signal; 2006; 8(9-10):1677-91. PubMed ID: 16987021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Practical Review of Proteasome Pharmacology.
    Thibaudeau TA; Smith DM
    Pharmacol Rev; 2019 Apr; 71(2):170-197. PubMed ID: 30867233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting proteasomes for cardioprotection.
    Yu X; Patterson E; Kem DC
    Curr Opin Pharmacol; 2009 Apr; 9(2):167-72. PubMed ID: 19097937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins.
    Lokireddy S; Kukushkin NV; Goldberg AL
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7176-85. PubMed ID: 26669444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasomes.
    Dahlmann B
    Essays Biochem; 2005; 41():31-48. PubMed ID: 16250896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turning-ON Proteasomes.
    Krahn JH; Kaschani F; Kaiser M
    Cell Chem Biol; 2017 Jun; 24(6):653-655. PubMed ID: 28644955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetogenic agent alloxan is a proteasome inhibitor.
    Zhou W; Wei L; Xiao T; Lai C; Peng M; Xu L; Luo X; Deng S; Zhang F
    Biochem Biophys Res Commun; 2017 Jun; 488(2):400-406. PubMed ID: 28502636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of ubiquitin proteasome pathway in cancer development.
    Yerlikaya A; Yöntem M
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases.
    Davies KJ; Shringarpure R
    Neurology; 2006 Jan; 66(2 Suppl 1):S93-6. PubMed ID: 16432154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial proteasomes as drug targets.
    Zhang H; Lin G
    PLoS Pathog; 2021 Dec; 17(12):e1010058. PubMed ID: 34882737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
    Di Napoli M; McLaughlin B
    Curr Opin Investig Drugs; 2005 Jul; 6(7):686-99. PubMed ID: 16044664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome and cancer.
    Catalgol B
    Prog Mol Biol Transl Sci; 2012; 109():277-93. PubMed ID: 22727425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.